Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.

Dam, TienBoxer, Adam LGolbe, Lawrence IHöglinger, Günter UMorris, Huw RLitvan, IreneLang, Anthony ECorvol, Jean-ChristopheAiba, IkukoGrundman, MichaelYang, LiliTidemann-Miller, BethKupferman, JosephHarper, KristineKamisoglu, KubraWald, Michael JGraham, Danielle LGedney, LizO'Gorman, JohnHaeberlein, Samantha BuddPASSPORT Study Group2023-05-032023-05-032022-10-17http://hdl.handle.net/10668/19574enAuthor Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.research article36253611open access10.1038/s41591-022-02076-81546-170Xhttps://www.nature.com/articles/s41591-022-02076-8.pdf